Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLC008
MIFTS: 40

Glucose Metabolism Disease

Categories: Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glucose Metabolism Disease

About this section

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 15 17
Glucose Metabolism Disorders 43 71
Disorder of Glucose Metabolism 12

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4194
MeSH 43 D044882
NCIt 49 C53655
UMLS 71 C1257958
Sources

Summaries for Glucose Metabolism Disease

About this section
MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to diabetes mellitus and abdominal obesity-metabolic syndrome 1. An important gene associated with Glucose Metabolism Disease is PINK1-AS (PINK1 Antisense RNA), and among its related pathways/superpathways are MicroRNAs in cancer and Folate Metabolism. The drugs Insulin glargine and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney.

Sources

Related Diseases for Glucose Metabolism Disease

About this section

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus 33.1 MIR223 MIR17 MIR155 MIR146A MIR126 LEP
2 abdominal obesity-metabolic syndrome 1 31.5 LEP INS GCG ADIPOQ
3 liver disease 31.5 SERPINA3 LEP INS ALB ADIPOQ
4 liver cirrhosis 31.4 SERPINA3 MIR199A1 LEP ALB ADIPOQ
5 sleep apnea 31.4 LEP INS CRP ALB ADIPOQ
6 fatty liver disease 31.4 LEP INS CRP ALB ADIPOQ
7 coronary heart disease 1 31.3 MIR17 MIR155 MIR126 INS CRP ADIPOQ
8 hyperglycemia 31.2 MIR126 LEP INS GCG ALB ADIPOQ
9 non-alcoholic fatty liver disease 31.2 MIR21 MIR17 MIR126 LEP INS GCG
10 diabetes mellitus, ketosis-prone 31.2 INS GCG ALB
11 pre-eclampsia 31.2 MIR126 LEP INS CRP ALB ADIPOQ
12 hepatocellular carcinoma 31.2 SERPINA3 MIR223 MIR21 MIR199A1 MIR17 MIR155
13 polycystic ovary syndrome 31.1 LEP INS CRP ADIPOQ
14 acute cystitis 31.0 INS H2AC18 CRP CCR6 ALB
15 prediabetes syndrome 31.0 SERPINA3 MIR126 LEP INS GCG CRP
16 myeloma, multiple 31.0 MIR21 MIR199A1 MIR17 MIR155 MIR142 MIR126
17 diabetes mellitus, insulin-dependent 31.0 LEP INS ICOSLG H2AC18 GCG CRP
18 lipid metabolism disorder 31.0 MIR126 LEP INS H2AC18 CRP ADIPOQ
19 cerebrovascular disease 31.0 SERPINA3 MIR21 MIR199A1 LEP INS CRP
20 pulmonary disease, chronic obstructive 31.0 SERPINA3 MIR28 MIR199A1 MIR142 MIR126 INS
21 microvascular complications of diabetes 5 31.0 MIR21 MIR126 INS H2AC18 ALB
22 glucose intolerance 31.0 LEP INS GCG CRP ALB ADIPOQ
23 gestational diabetes 31.0 LEP INS GCG CRP ADIPOQ
24 placenta disease 31.0 SERPINA3 INS H2AC18 CRP ADIPOQ
25 hyperuricemia 31.0 LEP INS CRP ALB
26 arteriosclerosis 31.0 MIR21 MIR155 MIR142 MIR126 INS CRP
27 uremia 31.0 LEP INS CRP ALB
28 coronary artery anomaly 31.0 MIR223 MIR21 MIR199A1 MIR126 CRP ALB
29 fatty liver disease, nonalcoholic 1 31.0 LEP INS ADIPOQ
30 proteasome-associated autoinflammatory syndrome 1 31.0 INS CRP ALB ADIPOQ
31 diabetes mellitus, noninsulin-dependent 31.0 SERPINA3 MIR28 MIR21 MIR199A1 MIR17 MIR146A
32 microvascular complications of diabetes 3 30.9 MIR21 INS ALB
33 prader-willi syndrome 30.9 LEP INS H2AC18 GCG ADIPOQ
34 pancreatitis 30.9 MIR21 INS GCG CRP
35 esophageal cancer 30.9 MIR223 MIR21 MIR199A1 MIR155 MIR146A MIR142
36 body mass index quantitative trait locus 11 30.9 SERPINA3 MIR28 MIR223 MIR21 MIR199A1 MIR17
37 arteries, anomalies of 30.9 SERPINA3 MIR28 MIR223 MIR21 MIR199A1 MIR17
38 hyperinsulinism 30.9 LEP INS GCG ADIPOQ
39 pancreatic cancer 30.9 MIR223 MIR21 MIR199A1 MIR17 MIR155 MIR146A
40 macular degeneration, age-related, 1 30.9 SERPINA3 INS H2AC18 CRP ALB
41 respiratory failure 30.6 SERPINA3 H2AC18 CRP ALB
42 hypoglycemia 11.2
43 triosephosphate isomerase deficiency 11.2
44 autoimmune disease 11.0 MIR146A INS ICOSLG CRP CCR6
45 bacterial infectious disease 11.0 SERPINA3 MIR155 ICOSLG H2AC18 CRP CCR6
46 gastrointestinal system benign neoplasm 11.0 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 INS
47 endocrine organ benign neoplasm 11.0 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
48 thyroid gland disease 10.9 MIR21 MIR199A1 MIR17 MIR146A MIR142 INS
49 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR21 MIR199A1 MIR17 ICOSLG H2AC18
50 ovary epithelial cancer 10.9 SERPINA3 MIR21 MIR199A1 MIR17 ICOSLG H2AC18

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease
Sources

Symptoms & Phenotypes for Glucose Metabolism Disease

About this section
Sources

Drugs & Therapeutics for Glucose Metabolism Disease

About this section

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1
2
Zidovudine Approved Phase 4 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Lopinavir Approved Phase 4 192725-17-0 92727
5
Insulin aspart Approved Phase 4 116094-23-6 16132418
6
Sertraline Approved Phase 4 79617-96-2 68617
7
Metformin Approved Phase 4 657-24-9 14219 4091
8
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
9
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
10 Neurotransmitter Agents Phase 4
11 Psychotropic Drugs Phase 4
12 HIV Protease Inhibitors Phase 4
13 Cytochrome P-450 CYP3A Inhibitors Phase 4
14
protease inhibitors Phase 4
15 Anti-Retroviral Agents Phase 4
16 Reverse Transcriptase Inhibitors Phase 4
17 Lamivudine, zidovudine drug combination Phase 4
18 Anti-HIV Agents Phase 4
19 Antidepressive Agents Phase 4
20 Black Currant Phase 4
21 Serotonin Uptake Inhibitors Phase 4
22 Serotonin Agents Phase 4
23 Insulin, Long-Acting Phase 4
24 Insulin degludec, insulin aspart drug combination Phase 4
25 Ferric Compounds Phase 4
26 Sodium-Glucose Transporter 2 Inhibitors Phase 4
27 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
28
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
29
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
30
Liraglutide Approved Phase 3 204656-20-2 44147092
31
Glimepiride Approved Phase 3 93479-97-1 3476
32
Gliclazide Approved Phase 3 21187-98-4 3475
33
Glyburide Approved Phase 3 10238-21-8 3488
34
Alogliptin Approved Phase 3 850649-61-5 11450633
35
Ramipril Approved Phase 3 87333-19-5 5362129
36
Calcium carbonate Approved, Investigational Phase 3 471-34-1
37
Fenofibrate Approved Phase 3 49562-28-9 3339
38
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
39
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
40
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
41
Bupropion Approved Phase 3 34911-55-2, 34841-39-9 444
42
Ethanol Approved Phase 3 64-17-5 702
43 Nutmeg Approved Phase 3
44 Hormone Antagonists Phase 3
45 Incretins Phase 3
46 Cardiac Glycosides Phase 3
47 Glycoside Hydrolase Inhibitors Phase 3
48 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 3
49 Anti-Arrhythmia Agents Phase 3
50 Sitagliptin Phosphate Phase 3

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements Completed NCT00483769 Phase 4 Glargine
2 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
3 A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism Completed NCT00192621 Phase 4 Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr])
4 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study Completed NCT02689765 Phase 4
5 Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent Completed NCT00834652 Phase 4 Sertraline;Metformin
6 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
7 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
8 Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes Recruiting NCT02744976 Phase 4 Metformin
9 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
10 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
11 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia. Completed NCT00349128 Phase 2, Phase 3 fenofibrate and metformin combination (drug)
12 An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia Completed NCT00348725 Phase 3 fenofibrate and metformin fixed combination (drug)
13 Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) Completed NCT00221156 Phase 3 Acarbose
14 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00736879 Phase 3 Dapagliflozin;Placebo
15 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
16 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT01841697 Phase 3 Omarigliptin;Sitagliptin;Placebo to omarigliptin;Placebo to Sitagliptin;Open-label Metformin;Open-label Glimepiride
17 A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00859898 Phase 3 Dapagliflozin;Metformin XR;Metformin XR;dapagliflozin matching Placebo;metformin HCl Modified Release matching Placebo
18 An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting Completed NCT01340768 Phase 3 Sitagliptin;Sulfonylurea;Metformin
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Completed NCT01137474 Phase 3 Dapagliflozin;Placebo-matching dapagliflozin
20 A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin. Completed NCT00362323 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Metformin
21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome Completed NCT00968708 Phase 3 Alogliptin;Placebo
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
23 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Completed NCT01814748 Phase 3 Omarigliptin;Placebo to omarigliptin;Metformin
24 Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia Completed NCT02092896 Phase 3 Liraglutide;Placebo;Liraglutide;Placebo
25 The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial Completed NCT00095654 Phase 3 Ramipril;Rosiglitazone
26 Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) Recruiting NCT03730662 Phase 3 Tirzepatide;Insulin Glargine
27 A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Terminated NCT00361868 Phase 3 fenofibrate (F) + metformin (M) hydrochloride fixed combination;Rosiglitazone
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR Terminated NCT01601704 Phase 3 NB32;PBO
29 Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation Terminated NCT00935766 Phase 3 Omega-3;Placebo
30 Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose. Unknown status NCT02102737 Phase 2 6-DIG
31 Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes Completed NCT01001104 Phase 2 LY2189265;Placebo
32 A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults Completed NCT00600067 Phase 2 Phentermine/Topiramate;Placebo
33 A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus Completed NCT02004886 Phase 2 MK-0893;Metformin;Placebo;Placebo
34 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
35 Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes Completed NCT02464033 Phase 2 GAD-Alum;Vitamin D;Etanercept
36 The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device Completed NCT01073566 Phase 2
37 Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans Completed NCT01354977 Phase 2 Resveratrol
38 Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation Completed NCT01354964 Phase 2 Vitamin D;Placebo
39 A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study. Completed NCT01261494 Phase 2 GFT505 80mg;Placebo
40 Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen Completed NCT01785108 Phase 2 Vitamin D;Ibuprofen
41 A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia Completed NCT02771574 Phase 2 Exendin (9-39)
42 Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes Completed NCT01935804 Phase 2 Pioglitazone;Metformin
43 A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients Completed NCT02733588 Phase 2 G-Pump™ (glucagon infusion)
44 Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus Completed NCT02644759 Phase 1, Phase 2
45 An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes Completed NCT01778348 Phase 2
46 Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans Recruiting NCT03486223 Phase 2 GSK2256294;Placebo oral capsule
47 Acute Metabolic Effects of Melatonin Treatment Recruiting NCT03204877 Phase 1, Phase 2 Melatonin
48 Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D) Recruiting NCT03181399 Phase 2 Triheptanoin
49 Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide Recruiting NCT03566511 Phase 2 Diazoxide;Placebo
50 Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Recruiting NCT03682640 Phase 2 Azithromycin Monohydrate;Insulin Lispro

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Sources

Genetic Tests for Glucose Metabolism Disease

About this section
Sources

Anatomical Context for Glucose Metabolism Disease

About this section

MalaCards organs/tissues related to Glucose Metabolism Disease:

40
Liver, Heart, Kidney, Bone, Skin, Thyroid, Lymph Node
Sources

Publications for Glucose Metabolism Disease

About this section

Articles related to Glucose Metabolism Disease:

(show top 50) (show all 203)
# Title Authors PMID Year
1
Glucose metabolism disorders in children with refractory nephrotic syndrome. 61
31950245 2020
2
Prevalence of undiagnosed glucose intolerance and type 2 diabetes in patients with moderate-to-severe obstructive sleep apnea syndrome. 61
31838624 2019
3
High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling. 61
31634780 2019
4
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study. 61
31829160 2019
5
Agenesis of the dorsal pancreas presenting with diabetic ketoacidosis - a case report and literature review. 61
31711495 2019
6
Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. 61
31721134 2019
7
Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice. 61
31089202 2019
8
Protective effects of melatonin on sepsis-induced liver injury and dysregulation of gluconeogenesis in rats through activating SIRT1/STAT3 pathway. 61
31234024 2019
9
Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice. 61
31054103 2019
10
[Bone microarchitecture and other body composition parameters in patients with overweight or obesity grouped by glucose metabolism disorders]. 61
31192689 2019
11
Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. 61
31144451 2019
12
Extensive metabolic remodeling after limiting mitochondrial lipid burden is consistent with an improved metabolic health profile. 61
31097541 2019
13
Low intake of digestible carbohydrates ameliorates duodenal absorption of carbohydrates in mice with glucose metabolism disorders induced by artificial sweeteners. 61
30953347 2019
14
Glucose Metabolism Abnormalities in Heart Failure Patients: Insights and Prognostic Relevance. 61
31079691 2019
15
Prevention of Cardiovascular Diseases in Children and Adolescents. 61
31041682 2019
16
Adipose Tissue Mediates Associations of Birth Weight with Glucose Metabolism Disorders in Children. 61
30811103 2019
17
Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center. 61
31137898 2019
18
The utilization and challenges of Japan's MID-NET® medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. 61
30945387 2019
19
Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. 61
31108989 2019
20
H2S promotes a glycometabolism disorder by disturbing the Th1/Th2 balance during LPS-induced inflammation in the skeletal muscles of chickens. 61
30703651 2019
21
Ammonia exposure induced abnormal expression of cytokines and heat shock proteins via glucose metabolism disorders in chicken neutrophils. 61
30767103 2019
22
Changes in glucose metabolism based on 75-g oral glucose tolerance tests before and after surgery for adrenal Cushing's syndrome. 61
30674738 2019
23
The ratio of fasting plasma glucose to hemoglobin A1c as a predictor of all-cause mortality in individuals with normal glucose levels: The Jichi Medical School cohort study. 61
31263559 2019
24
Influence of Maternal Inulin-Type Prebiotic Intervention on Glucose Metabolism and Gut Microbiota in the Offspring of C57BL Mice. 61
31632351 2019
25
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression. 61
30063256 2019
26
Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study. 61
31686868 2019
27
Potential role of liver enzyme levels as predictive markers of glucose metabolism disorders in a Tunisian population. 61
29527933 2018
28
Prediction of Glucose Metabolism Disorder Risk Using a Machine Learning Algorithm: Pilot Study. 61
30478026 2018
29
Maternal lipopolysaccharide exposure results in glucose metabolism disorders and sex hormone imbalance in male offspring. 61
29614340 2018
30
Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats. 61
29209957 2018
31
Chlorogenic Acid Targeting of the AKT PH Domain Activates AKT/GSK3β/FOXO1 Signaling and Improves Glucose Metabolism. 61
30249058 2018
32
Dynapenic obesity as an associated factor to lipid and glucose metabolism disorders and metabolic syndrome in older adults - Findings from SABE Study. 61
28647293 2018
33
Pretransplantation Oral Glucose Tolerance Test Can Prevent Posttransplant Diabetes Mellitus After Renal Transplantation: Preliminary Study. 61
30056899 2018
34
Diabetes mellitus and insulin resistance associate with left ventricular shape and torsion by cardiovascular magnetic resonance imaging in asymptomatic individuals from the multi-ethnic study of atherosclerosis. 61
30064457 2018
35
Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. 61
29279271 2018
36
Impact of Glucose Metabolism Disorders on IGF-1 Levels in Patients with Acromegaly. 61
29642245 2018
37
Detection of glucose metabolism disorders in coronary patients enrolled in cardiac rehabilitation: Is glycated haemoglobin useful? Data from the prospective REHABDIAB study. 61
29370710 2018
38
Maternal educational level and the risk of persistent post-partum glucose metabolism disorders in women with gestational diabetes mellitus. 61
29288374 2018
39
Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. 61
29229354 2018
40
Aberrant expression of miR-451a contributes to 1,2-dichloroethane-induced hepatic glycerol gluconeogenesis disorder by inhibiting glycerol kinase expression in NIH Swiss mice. 61
28960355 2018
41
Heart in Acromegaly: The Echocardiographic Characteristics of Patients Diagnosed with Acromegaly in Various Stages of the Disease. 61
30123265 2018
42
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. 61
29227477 2018
43
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. 61
29910611 2018
44
Effect of Decaffeinated Coffee-enriched Chlorogenic Acid on Blood Glucose Levels in Healthy Controls: A Systematic Review. 61
30834096 2018
45
Over-expression of PPARα in obese mice adipose tissue improves insulin sensitivity. 61
28919422 2017
46
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer. 61
29303126 2017
47
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. 61
27739213 2017
48
Effect of vitamin D on HbA1c levels of children and adolescents with diabetes mellitus type 1. 61
25411949 2017
49
Examining the gut bacteriome, virome, and mycobiome in glucose metabolism disorders: Are we on the right track? 61
28732571 2017
50
Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. 61
28701081 2017
Sources

Variations for Glucose Metabolism Disease

About this section
Sources

Expression for Glucose Metabolism Disease

About this section
Search GEO for disease gene expression data for Glucose Metabolism Disease.
Sources

Pathways for Glucose Metabolism Disease

About this section

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.72 MIR28 MIR223 MIR21 MIR199A1 MIR17 MIR155
2
Folate Metabolism 1
Show member pathways
 11.59 SERPINA3 INS CRP ALB
Sources

GO Terms for Glucose Metabolism Disease

About this section

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.53 ADIPOQ ALB CRP GCG INS LEP

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 MIR223 MIR21 MIR155 MIR146A INS CRP
2 positive regulation of inflammatory response GO:0050729 9.81 MIR21 MIR155 MIR126
3 cellular response to hypoxia GO:0071456 9.81 MIR17 MIR155 MIR146A MIR126
4 glucose metabolic process GO:0006006 9.76 LEP INS ADIPOQ
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 MIR21 MIR126 LEP INS
6 positive regulation of protein kinase B signaling GO:0051897 9.72 MIR21 MIR199A1 MIR126 LEP INS
7 positive regulation of glucose import GO:0046326 9.71 MIR223 INS ADIPOQ
8 acute-phase response GO:0006953 9.7 SERPINA3 INS CRP
9 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.67 MIR223 MIR21 MIR146A
10 positive regulation of activated T cell proliferation GO:0042104 9.65 MIR21 MIR155 ICOSLG
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.64 CRP ADIPOQ
12 positive regulation of microglial cell activation GO:1903980 9.63 MIR155 MIR142
13 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.62 MIR155 MIR146A
14 negative regulation of blood vessel diameter GO:0097756 9.62 INS CRP
15 negative regulation of cartilage development GO:0061037 9.61 MIR21 LEP
16 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
17 negative regulation of lipid storage GO:0010888 9.6 LEP CRP
18 negative regulation of regulatory T cell differentiation GO:0045590 9.59 MIR21 MIR155
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR21 MIR17
20 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.58 MIR223 MIR21 ADIPOQ
21 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.57 MIR155 MIR146A
22 negative regulation of necrotic cell death GO:0060547 9.56 MIR223 MIR155
23 negative regulation of protein oligomerization GO:0032460 9.55 INS ALB
24 negative regulation of inflammatory response GO:0050728 9.55 MIR223 MIR155 MIR146A MIR126 ADIPOQ
25 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.54 MIR199A1 MIR17 MIR155
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR199A1 MIR17 MIR155
27 miRNA mediated inhibition of translation GO:0035278 9.35 MIR28 MIR21 MIR17 MIR155 MIR146A
28 gene silencing by miRNA GO:0035195 9.17 MIR223 MIR21 MIR199A1 MIR17 MIR155 MIR146A

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.26 LEP INS GCG ADIPOQ
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR28 MIR223 MIR21 MIR199A1 MIR17 MIR155
Sources

Sources for Glucose Metabolism Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....